Sari Pesonen gained her PhD in biology from the University of Turku, Finland in 2007. She continued her academic career in University of Helsinki in a research group focusing on development of oncolytic viruses for the treatment of cancer.
In January 2008, she was awarded a prestigious three-year post-doctoral research post by the Academy of Finland. During her 6-year postdoctoral training, she co-supervised 3 PhD students and is a co-author in 60+ peer-reviewed research papers.
In 2013, she moved to biotech company Oncos Therapeutics and worked first as a Research Director and later as a Head of Clinical Science. Oncos Therapeutics was merged with a Norwegian biotech company Targovax and in a merged company she continued as a VP, Preclinical Research and Clinical Science until May 2016.
In May 2016, Sari co-founded a University spin out company Valo Therapeutics (PeptiCRAd Oy).